Hoppa till innehållet

OMXSPI+0,50%

S&P 500+0,80%

FTSE 100+0,54%

DAX+0,01%

NIKKEI+1,14%
Redeye: Moberg Pharma Q4’2023 - Lots of progress in a short time

Redeye sees the end-of-year report as results as uneventful. More important were the indications of a good start to the Swedish launch, the conclusion of the enrollment to the Phase 3 study, and progress regarding the Terbinafine supply. These factors are essential next steps for Moberg Pharma’s commercialization of MOB-015. The national approvals in the remaining countries in the DCP process are in process and will be approved.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Moberg Pharma Q4’2023 - Lots of progress in a short time

Source:MFN
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill du bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1180kr
Prenumerera